stockrowImmatics N.V.
IMTX Healthcare Biotechnology
Immatics N.V.’s revenue for fiscal 2025 (year ended December 2025) was $54.6 million, down 67.6% from fiscal 2024.
- Revenue
- +97.7%
- EPS
- +19.7%
- Free cash flow
- −44.4%
Quarter to June 2026, against a year earlier
Follow IMTX
Alert me
Immatics N.V. (IMTX) EV/Sales
As of 6 November 2026, Immatics N.V. (IMTX) trades at a EV/Sales of 12.1×. Over the past ten years it has ranged from 0.0× (September 2020) to 27.6× (May 2026); the current reading is higher than 72% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 16.4× | 456.51% |
| FY2024 | 2.9× | (72.60%) |
| FY2023 | 10.7× | 365.61% |
| FY2022 | 2.3× | (86.23%) |
| FY2021 | 16.7× | 110.29% |
| FY2020 | 8.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 22.7× | 2.37% |
| Mar 2026 | 22.1× | 35.26% |
| Dec 2025 | 16.4× | 131.04% |
| Sep 2025 | 7.1× | 174.37% |
| 23 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ODTX Odyssey Therapeutics, Inc. compare | n/m |
| ORIC Oric Pharmaceuticals, Inc. compare | n/m |
| MLTX MoonLake Immunotherapeutics compare | n/m |
| SVRA Savara Inc. compare | n/m |
| JBIO Jade Biosciences, Inc. compare | n/m |
| JANX Janux Therapeutics, Inc. compare | 5.0× |
| GLUE Monte Rosa Therapeutics, Inc. compare | 7.0× |
| IMTX Immatics N.V. | 12.1× |
| CTY City Therapeutics, Inc compare | — |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)